SIMILAR PATTERNS OF AMINO ACIDS FOR 5L2T_A_6ZZA900_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 133 ALA A 143	None	0.70A	5l2tA-1h4lA: 14.5	5l2tA-1h4lA: 45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 133	None	0.90A	5l2tA-1h4lA: 14.5	5l2tA-1h4lA: 45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133	None	0.79A	5l2tA-1h4lA: 14.5	5l2tA-1h4lA: 45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133 ALA A 143	None	0.67A	5l2tA-1h4lA: 14.5	5l2tA-1h4lA: 45.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	9	ILE A 580 GLY A 581 VAL A 588 ALA A 606 VAL A 638 PHE A 654 ASP A 661 LEU A 731 ALA A 741	None	0.87A	5l2tA-1lufA: 7.1	5l2tA-1lufA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 638 PHE A 654 ASP A 661 LEU A 731 ALA A 741 ASP A 742	None	0.83A	5l2tA-1lufA: 7.1	5l2tA-1lufA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.86A	5l2tA-1rjbA: 6.6	5l2tA-1rjbA: 25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 370 VAL A 377 ALA A 389 VAL A 419 PHE A 435 LEU A 489	None	0.86A	5l2tA-1snxA: 8.5	5l2tA-1snxA: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 596 VAL A 603 ALA A 621 VAL A 654 ASP A 677 LEU A 799	None STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-4.3A) None STI A 3 (-4.4A)	0.89A	5l2tA-1t46A: 22.1	5l2tA-1t46A: 26.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	7	ALA A 30 VAL A 63 PHE A 79 HIS A 81 ASP A 85 LEU A 132 ASP A 143	None	1.08A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	8	GLY A 11 ALA A 30 VAL A 63 PHE A 79 HIS A 81 ASP A 85 LEU A 132 ALA A 142	None	0.67A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	8	GLY A 11 VAL A 18 ALA A 30 VAL A 63 PHE A 79 HIS A 81 LEU A 132 ALA A 142	None	0.74A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	8	ILE A 10 GLY A 11 ALA A 30 VAL A 63 PHE A 79 HIS A 81 ASP A 85 LEU A 132	None	1.06A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	8	ILE A 10 GLY A 11 VAL A 18 ALA A 30 VAL A 63 PHE A 79 HIS A 81 LEU A 132	None	1.05A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	7	VAL A 18 ALA A 30 VAL A 63 PHE A 79 HIS A 81 LEU A 132 ASP A 143	None	1.21A	5l2tA-1v0bA: 17.5	5l2tA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 184 VAL A 220 PHE A 236 LEU A 290 ALA A 319 ASP A 320	None	0.83A	5l2tA-2eu9A: 11.7	5l2tA-2eu9A: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 163 VAL A 170 ALA A 184 VAL A 220 PHE A 236 LEU A 290 ALA A 319	None	0.83A	5l2tA-2eu9A: 11.7	5l2tA-2eu9A: 30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 249 VAL A 256 ALA A 269 VAL A 299 LEU A 370 ALA A 380	None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.6A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.74A	5l2tA-2hz0A: 23.2	5l2tA-2hz0A: 25.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 134 ALA A 144	None	0.80A	5l2tA-2jgzA: 19.3	5l2tA-2jgzA: 48.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 11 VAL A 64 PHE A 80 ASP A 86 LEU A 134 ALA A 144 ASP A 145	None	0.93A	5l2tA-2jgzA: 19.3	5l2tA-2jgzA: 48.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 GLY A 11 VAL A 18 ALA A 31 PHE A 80 ASP A 86 LEU A 134	None	1.03A	5l2tA-2jgzA: 19.3	5l2tA-2jgzA: 48.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 GLY A 429 VAL A 436 ALA A 452 VAL A 484 LEU A 553	BII A1687 (-3.8A) BII A1687 ( 3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) None BII A1687 (-4.2A)	0.97A	5l2tA-2jkmA: 10.4	5l2tA-2jkmA: 26.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2pmi	CYCLIN-DEPENDENT PROTEIN KINASE PHO85 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 21 ALA A 34 VAL A 66 PHE A 82 ASP A 88 LEU A 140	AGS A3001 (-4.4A) AGS A3001 (-3.5A) None None None None	0.91A	5l2tA-2pmiA: 14.5	5l2tA-2pmiA: 41.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 83 VAL A 90 ALA A 103 VAL A 137 ASP A 160 LEU A 205 ALA A 215	ANP A1480 ( 4.3A) None ANP A1480 ( 3.9A) ANP A1480 (-4.7A) ANP A1480 (-4.0A) ANP A1480 ( 4.7A) ANP A1480 ( 4.1A)	0.92A	5l2tA-2v55A: 7.5	5l2tA-2v55A: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 82 GLY A 83 VAL A 90 ALA A 103 VAL A 137 ASP A 160 LEU A 205	None ANP A1480 ( 4.3A) None ANP A1480 ( 3.9A) ANP A1480 (-4.7A) ANP A1480 (-4.0A) ANP A1480 ( 4.7A)	1.21A	5l2tA-2v55A: 7.5	5l2tA-2v55A: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vd5	DMPK PROTEIN (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 85 ALA A 98 ASP A 155 THR A 158 LEU A 202 ALA A 212	BI8 A1417 ( 4.7A) BI8 A1417 ( 3.8A) None None BI8 A1417 (-4.8A) BI8 A1417 ( 4.1A)	0.79A	5l2tA-2vd5A: 5.3	5l2tA-2vd5A: 24.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	9	GLY B 13 ALA B 33 VAL B 72 PHE B 93 HIS B 95 ASP B 99 THR B 102 LEU B 147 ALA B 157	None	0.72A	5l2tA-2w9fB: 12.0	5l2tA-2w9fB: 69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	7	GLY B 13 HIS B 95 ASP B 99 THR B 102 LEU B 147 ALA B 157 ASP B 158	None	1.07A	5l2tA-2w9fB: 12.0	5l2tA-2w9fB: 69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	7	GLY B 15 ALA B 33 VAL B 72 PHE B 93 ASP B 99 LEU B 147 ALA B 157	None	1.45A	5l2tA-2w9fB: 12.0	5l2tA-2w9fB: 69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	10	ILE B 12 GLY B 13 VAL B 20 ALA B 33 VAL B 72 PHE B 93 HIS B 95 THR B 102 LEU B 147 ALA B 157	None	0.93A	5l2tA-2w9fB: 12.0	5l2tA-2w9fB: 69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	8	ILE B 12 GLY B 13 VAL B 20 HIS B 95 THR B 102 LEU B 147 ALA B 157 ASP B 158	None	1.29A	5l2tA-2w9fB: 12.0	5l2tA-2w9fB: 69.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 69 VAL A 76 ALA A 92 VAL A 125 ASP A 148 THR A 151 LEU A 194	STU A 1 (-3.3A) None STU A 1 (-3.3A) None STU A 1 (-3.8A) None STU A 1 (-4.6A)	0.87A	5l2tA-2z7rA: 8.7	5l2tA-2z7rA: 29.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3bhh	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II BETA CHAIN (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 28 ALA A 41 VAL A 74 PHE A 90 LEU A 143 ALA A 156 ASP A 157	5CP A 600 ( 4.4A) 5CP A 600 (-3.6A) 5CP A 600 ( 4.7A) 5CP A 600 ( 4.3A) 5CP A 600 (-4.4A) 5CP A 600 ( 3.9A) 5CP A 600 (-3.5A)	0.77A	5l2tA-3bhhA: 7.4	5l2tA-3bhhA: 30.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 18 GLY A 19 VAL A 26 ALA A 39 VAL A 75 PHE A 91 LEU A 148	3AM A 338 (-4.5A) None 3AM A 338 ( 4.1A) 3AM A 338 (-3.3A) None 3AM A 338 (-3.6A) 3AM A 338 (-4.7A)	1.12A	5l2tA-3c0iA: 7.8	5l2tA-3c0iA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 23 GLY A 24 VAL A 31 ALA A 44 VAL A 76 LEU A 153 ALA A 163	ANP A 1 (-4.2A) ANP A 1 (-3.3A) ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None MG A 296 ( 3.9A)	0.93A	5l2tA-3dakA: 22.1	5l2tA-3dakA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 45 VAL A 52 ALA A 65 ASP A 128 LEU A 174 ASP A 186	985 A 1 ( 3.9A) 985 A 1 (-4.5A) 985 A 1 (-3.5A) 985 A 1 (-4.7A) 985 A 1 (-4.8A) 985 A 1 ( 4.0A)	0.94A	5l2tA-3f2aA: 7.8	5l2tA-3f2aA: 26.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	9	ILE A 25 GLY A 26 VAL A 33 ALA A 46 VAL A 79 PHE A 103 ASP A 109 LEU A 156 ALA A 166	None	0.83A	5l2tA-3mi9A: 12.9	5l2tA-3mi9A: 36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 79 PHE A 103 ASP A 109 LEU A 156 ALA A 166 ASP A 167	None	0.73A	5l2tA-3mi9A: 12.9	5l2tA-3mi9A: 36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 172 VAL A 179 ALA A 192 VAL A 224 PHE A 240 ASP A 246 LEU A 293	FEF A 668 ( 4.2A) FEF A 668 (-4.9A) FEF A 668 (-3.3A) FEF A 668 (-4.7A) FEF A 668 ( 4.3A) FEF A 668 ( 4.3A) FEF A 668 (-4.2A)	0.85A	5l2tA-3mtlA: 18.2	5l2tA-3mtlA: 39.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 179 ALA A 192 VAL A 224 PHE A 240 ASP A 246 LEU A 293 ALA A 303	FEF A 668 (-4.9A) FEF A 668 (-3.3A) FEF A 668 (-4.7A) FEF A 668 ( 4.3A) FEF A 668 ( 4.3A) FEF A 668 (-4.2A) FEF A 668 ( 4.0A)	0.87A	5l2tA-3mtlA: 18.2	5l2tA-3mtlA: 39.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3oz6	MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE/THREONINE PROTEIN KINASE (Cryptosporidium parvum)	PF00069 (Pkinase)	7	VAL A 25 ALA A 38 VAL A 72 PHE A 90 ASP A 96 LEU A 141 ALA A 151	None	0.91A	5l2tA-3oz6A: 14.3	5l2tA-3oz6A: 30.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qfv	CDC42BPB PROTEIN (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 83 VAL A 90 ALA A 103 ASP A 160 THR A 163 LEU A 207 ALA A 217	NM7 A 416 (-3.0A) NM7 A 416 (-3.7A) NM7 A 416 ( 3.7A) None None NM7 A 416 ( 4.2A) NM7 A 416 ( 4.5A)	0.80A	5l2tA-3qfvA: 6.8	5l2tA-3qfvA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qfv	CDC42BPB PROTEIN (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 83 VAL A 90 ASP A 160 THR A 163 LEU A 207 ALA A 217 ASP A 218	NM7 A 416 (-3.0A) NM7 A 416 (-3.7A) None None NM7 A 416 ( 4.2A) NM7 A 416 ( 4.5A) EDO A 417 (-3.7A)	0.89A	5l2tA-3qfvA: 6.8	5l2tA-3qfvA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qfv	CDC42BPB PROTEIN (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 82 GLY A 83 VAL A 90 ALA A 103 ASP A 160 THR A 163 LEU A 207	None NM7 A 416 (-3.0A) NM7 A 416 (-3.7A) NM7 A 416 ( 3.7A) None None NM7 A 416 ( 4.2A)	1.10A	5l2tA-3qfvA: 6.8	5l2tA-3qfvA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	GLY A 362 VAL A 369 ALA A 382 ASP A 440 LEU A 486 ALA A 496	07U A 1 ( 4.2A) 07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 (-3.9A) 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	0.86A	5l2tA-3txoA: 19.9	5l2tA-3txoA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 552 ALA A 570 VAL A 601 PHE A 617 ASP A 624 LEU A 686	None 0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) None 0F4 A 902 (-4.5A)	0.86A	5l2tA-3v5qA: 21.9	5l2tA-3v5qA: 27.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 76 VAL A 83 ALA A 96 VAL A 128 HIS A 146 LEU A 198	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) ANP A 401 ( 4.9A) ANP A 401 (-4.8A)	0.87A	5l2tA-3wigA: 7.2	5l2tA-3wigA: 31.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A)	0.75A	5l2tA-4aguA: 17.1	5l2tA-4aguA: 35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 568 ALA A 586 VAL A 617 PHE A 633 ASP A 640 LEU A 699	None LTI A1839 (-3.3A) None LTI A1839 (-3.5A) None LTI A1839 (-4.2A)	0.86A	5l2tA-4at3A: 6.8	5l2tA-4at3A: 27.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	GLY A 84 ALA A 104 ASP A 161 THR A 164 LEU A 208 ALA A 218	None EDO A1420 (-3.4A) None None EDO A1420 ( 4.8A) None	0.95A	5l2tA-4aw2A: 7.0	5l2tA-4aw2A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	GLY A 84 ASP A 161 THR A 164 LEU A 208 ALA A 218 ASP A 219	None None None EDO A1420 ( 4.8A) None None	0.94A	5l2tA-4aw2A: 7.0	5l2tA-4aw2A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	ILE A 83 VAL A 91 ALA A 104 ASP A 161 THR A 164 LEU A 208	None None EDO A1420 (-3.4A) None None EDO A1420 ( 4.8A)	0.98A	5l2tA-4aw2A: 7.0	5l2tA-4aw2A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 91 ALA A 104 ASP A 161 THR A 164 LEU A 208 ALA A 218	None EDO A1420 (-3.4A) None None EDO A1420 ( 4.8A) None	0.73A	5l2tA-4aw2A: 7.0	5l2tA-4aw2A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 91 ASP A 161 THR A 164 LEU A 208 ALA A 218 ASP A 219	None None None EDO A1420 ( 4.8A) None None	0.78A	5l2tA-4aw2A: 7.0	5l2tA-4aw2A: 25.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4bbm	CYCLIN-DEPENDENT KINASE-LIKE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133 ASP A 144	None TC0 A 500 (-3.5A) TC0 A 500 (-4.7A) TC0 A 500 (-3.4A) TC0 A 500 (-4.3A) TC0 A 500 (-4.8A)	0.71A	5l2tA-4bbmA: 13.9	5l2tA-4bbmA: 33.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 43 VAL A 50 ALA A 63 VAL A 94 LEU A 164 ALA A 174	XZN A1317 ( 4.9A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.93A	5l2tA-4bc6A: 20.7	5l2tA-4bc6A: 28.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4bgq	CYCLIN-DEPENDENT KINASE-LIKE 5 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 20 VAL A 27 ALA A 40 VAL A 73 PHE A 89 LEU A 142	None 38R A1000 ( 4.8A) 38R A1000 (-3.4A) None 38R A1000 ( 3.8A) 38R A1000 ( 4.5A)	0.68A	5l2tA-4bgqA: 17.1	5l2tA-4bgqA: 35.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 671 ALA A 684 VAL A 721 ASP A 744 LEU A 789 ALA A 799	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-4.0A) AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.74A	5l2tA-4crsA: 8.0	5l2tA-4crsA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690 ASP A 701	GUI A 901 (-3.4A) None GUI A 901 ( 4.8A) GUI A 901 ( 3.8A) GUI A 901 (-4.3A) GUI A 901 ( 4.1A)	0.86A	5l2tA-4e93A: 7.7	5l2tA-4e93A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ILE A 567 GLY A 568 ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690	GUI A 901 (-4.0A) GUI A 901 ( 4.3A) GUI A 901 (-3.4A) None GUI A 901 ( 4.8A) GUI A 901 ( 3.8A) GUI A 901 (-4.3A)	1.01A	5l2tA-4e93A: 7.7	5l2tA-4e93A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	ILE A 567 GLY A 568 VAL A 575 ALA A 588 VAL A 620 ASP A 643 LEU A 690	GUI A 901 (-4.0A) GUI A 901 ( 4.3A) GUI A 901 (-4.5A) GUI A 901 (-3.4A) None GUI A 901 ( 4.8A) GUI A 901 (-4.3A)	1.01A	5l2tA-4e93A: 7.7	5l2tA-4e93A: 22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 20 VAL A 27 VAL A 77 PHE A 98 ASP A 104 THR A 106 LEU A 152	None None 0RS A 900 (-4.4A) 0RS A 900 (-4.5A) 0RS A 900 (-4.2A) None 0RS A 900 (-4.3A)	1.44A	5l2tA-4ez5A: 24.4	5l2tA-4ez5A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	12	ILE A 19 GLY A 20 VAL A 27 ALA A 41 VAL A 77 PHE A 98 HIS A 100 ASP A 104 THR A 107 LEU A 152 ALA A 162 ASP A 163	0RS A 900 (-4.1A) None None 0RS A 900 ( 3.7A) 0RS A 900 (-4.4A) 0RS A 900 (-4.5A) 0RS A 900 (-4.1A) 0RS A 900 (-4.2A) 0RS A 900 (-4.2A) 0RS A 900 (-4.3A) 0RS A 900 (-3.6A) 0RS A 900 (-3.6A)	0.66A	5l2tA-4ez5A: 24.4	5l2tA-4ez5A: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 516 VAL A 523 ALA A 541 VAL A 572 PHE A 588 ASP A 595 LEU A 656	None	0.91A	5l2tA-4f0iA: 21.9	5l2tA-4f0iA: 27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A1123 VAL A1130 ALA A1148 VAL A1180 ASP A1203 LEU A1256	0UV A1501 ( 4.3A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.9A) 0UV A1501 ( 4.6A) 0UV A1501 (-4.6A)	0.94A	5l2tA-4fodA: 7.5	5l2tA-4fodA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fzd	SERINE/THREONINE-PRO TEIN KINASE MST4 (Homo sapiens)	PF00069 (Pkinase)	6	ILE B 30 GLY B 31 VAL B 38 ALA B 51 LEU B 151 ALA B 161	GOL B1000 (-4.1A) None None GOL B1000 ( 4.3A) GOL B1000 ( 4.4A) None	0.64A	5l2tA-4fzdB: 23.8	5l2tA-4fzdB: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 829 VAL A 836 ALA A 853 VAL A 884 LEU A 956 ALA A 966	19S A1201 (-3.7A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.83A	5l2tA-4hviA: 23.1	5l2tA-4hviA: 26.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	ALA A 648 VAL A 685 ASP A 708 LEU A 753 ALA A 763 ASP A 764	None	0.93A	5l2tA-4otdA: 7.3	5l2tA-4otdA: 27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None None P30 A1001 (-3.4A) None P30 A1001 (-3.7A) None P30 A1001 (-4.6A)	0.81A	5l2tA-4rt7A: 6.8	5l2tA-4rt7A: 23.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None P30 A1001 ( 4.8A) P30 A1001 (-3.5A) None P30 A1001 ( 4.3A) None P30 A1001 (-4.3A)	0.76A	5l2tA-4xufA: 7.0	5l2tA-4xufA: 28.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 135 ALA A 145	None	0.88A	5l2tA-4yc6A: 14.8	5l2tA-4yc6A: 45.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 VAL A 64 ASP A 86 LEU A 135 ALA A 145 ASP A 146	None	0.98A	5l2tA-4yc6A: 14.8	5l2tA-4yc6A: 45.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 135 ALA A 145	None	0.69A	5l2tA-4yc6A: 14.8	5l2tA-4yc6A: 45.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 470 VAL A 477 ALA A 488 LEU A 595 ALA A 605 ASP A 606	4CV A 801 ( 3.9A) None 4CV A 801 (-3.5A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A) 4CV A 801 (-3.5A)	0.71A	5l2tA-4yffA: 21.3	5l2tA-4yffA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 165 GLY A 166 VAL A 173 ALA A 186 PHE A 238 LEU A 294	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.2A) None	0.83A	5l2tA-4yljA: 12.8	5l2tA-4yljA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 165 GLY A 166 VAL A 173 ALA A 186 VAL A 222 PHE A 238	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None 4E1 A 505 (-4.2A)	0.88A	5l2tA-4yljA: 12.8	5l2tA-4yljA: 29.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	6	GLY A 27 VAL A 34 ALA A 47 HIS A 98 LEU A 149 ALA A 159	None	0.97A	5l2tA-4ynzA: 12.2	5l2tA-4ynzA: 30.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 44 VAL A 76 ASP A 99 LEU A 145 ALA A 164	51W A 401 ( 4.3A) 51W A 401 (-3.4A) None 51W A 401 (-3.8A) 51W A 401 (-4.5A) None	0.69A	5l2tA-5ci7A: 8.1	5l2tA-5ci7A: 29.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	6	ILE A 81 GLY A 82 VAL A 89 ALA A 102 VAL A 134 LEU A 211	ANP A 401 ( 4.1A) ANP A 401 ( 3.9A) ANP A 401 (-4.0A) ANP A 401 ( 4.0A) None None	0.96A	5l2tA-5dbxA: 21.4	5l2tA-5dbxA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 600 VAL A 607 ALA A 625 VAL A 658 ASP A 681 LEU A 825	None 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 ( 4.8A) None 748 A1001 (-4.3A)	0.84A	5l2tA-5grnA: 6.7	5l2tA-5grnA: 26.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	6	GLY A 21 VAL A 28 ALA A 41 VAL A 74 PHE A 90 ALA A 156	ADP A 301 (-3.6A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None None ADP A 301 ( 4.8A)	0.83A	5l2tA-5hu3A: 7.8	5l2tA-5hu3A: 31.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 28 ALA A 50 PHE A 97 ASP A 103 LEU A 158 ALA A 172	6A7 A 401 (-3.6A) 6A7 A 401 (-3.3A) 6A7 A 401 (-3.8A) 6A7 A 401 ( 4.9A) 6A7 A 401 (-4.8A) 6A7 A 401 ( 4.1A)	0.83A	5l2tA-5idnA: 14.5	5l2tA-5idnA: 32.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 28 VAL A 35 ALA A 50 PHE A 97 LEU A 158 ALA A 172	6A7 A 401 (-3.6A) 6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) 6A7 A 401 (-3.8A) 6A7 A 401 (-4.8A) 6A7 A 401 ( 4.1A)	0.78A	5l2tA-5idnA: 14.5	5l2tA-5idnA: 32.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 23 VAL A 30 ALA A 43 VAL A 74 ALA A 153 ASP A 154	None 6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None 6G2 A 901 ( 4.2A) 6G2 A 901 (-3.4A)	0.94A	5l2tA-5j5tA: 20.7	5l2tA-5j5tA: 26.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 43 VAL A 74 LEU A 143 ALA A 153 ASP A 154	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A) 6G2 A 901 (-3.4A)	0.86A	5l2tA-5j5tA: 20.7	5l2tA-5j5tA: 26.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 396 GLY A 397 VAL A 404 ALA A 417 VAL A 449 ASP A 472 LEU A 518	GUI A 701 (-4.1A) GUI A 701 ( 3.8A) GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None None GUI A 701 (-4.4A)	1.14A	5l2tA-5jznA: 8.0	5l2tA-5jznA: 31.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 41 VAL A 49 ALA A 60 VAL A 94 ASP A 117 LEU A 163	STU A 901 (-4.3A) None STU A 901 (-3.3A) None STU A 901 (-4.2A) STU A 901 (-4.5A)	0.74A	5l2tA-5lohA: 8.4	5l2tA-5lohA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 155 GLY A 156 VAL A 163 ALA A 176 PHE A 228 LEU A 282	7A7 A 501 ( 4.3A) 7A7 A 501 (-3.2A) 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-3.7A) 7A7 A 501 (-4.9A)	0.86A	5l2tA-5lxdA: 16.3	5l2tA-5lxdA: 26.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 99 VAL A 106 ALA A 119 VAL A 157 PHE A 177 LEU A 232	W4A A 716 ( 4.0A) W4A A 716 ( 4.7A) W4A A 716 ( 3.9A) DMS A 717 (-4.3A) DMS A 717 ( 3.9A) None	0.94A	5l2tA-5myvA: 14.5	5l2tA-5myvA: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ncl	SERINE/THREONINE-PRO TEIN KINASE CBK1 (Saccharomyces cerevisiae)	no annotation	7	ILE A 358 GLY A 359 ALA A 379 VAL A 413 ASP A 436 THR A 439 LEU A 482	ANP A 801 (-4.2A) ANP A 801 ( 4.1A) ANP A 801 ( 3.9A) ANP A 801 ( 4.9A) ANP A 801 (-3.4A) None ANP A 801 (-4.8A)	0.86A	5l2tA-5nclA: 7.3	5l2tA-5nclA: 16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 98 GLY A 99 ALA A 119 VAL A 153 ASP A 176 LEU A 221 ALA A 231	None	1.13A	5l2tA-5u7qA: 7.6	5l2tA-5u7qA: 26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 98 VAL A 106 ALA A 119 VAL A 153 ASP A 176 LEU A 221 ALA A 231	None	1.13A	5l2tA-5u7qA: 7.6	5l2tA-5u7qA: 26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	7	ILE A 75 GLY A 76 VAL A 83 ALA A 95 VAL A 125 LEU A 206 ALA A 216	ANP A1000 (-4.2A) ANP A1000 ( 3.8A) ANP A1000 (-4.1A) ANP A1000 (-3.2A) None ANP A1000 (-4.5A) MG A1001 ( 4.4A)	0.98A	5l2tA-5xd6A: 6.3	5l2tA-5xd6A: 13.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	7	GLY A 734 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876 ASP A 877	CJM A1102 (-3.4A) None CJM A1102 ( 4.4A) CJM A1102 (-4.1A) CJM A1102 (-4.4A) CJM A1102 (-3.6A) MG A1101 (-2.5A)	0.96A	5l2tA-6b3eA: 13.4	5l2tA-6b3eA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	8	ILE A 733 GLY A 734 ALA A 754 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876	CJM A1102 (-3.4A) CJM A1102 (-3.4A) CJM A1102 (-3.1A) None CJM A1102 ( 4.4A) CJM A1102 (-4.1A) CJM A1102 (-4.4A) CJM A1102 (-3.6A)	1.03A	5l2tA-6b3eA: 13.4	5l2tA-6b3eA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	8	ILE A 733 VAL A 741 ALA A 754 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876	CJM A1102 (-3.4A) None CJM A1102 (-3.1A) None CJM A1102 ( 4.4A) CJM A1102 (-4.1A) CJM A1102 (-4.4A) CJM A1102 (-3.6A)	0.91A	5l2tA-6b3eA: 13.4	5l2tA-6b3eA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	VAL A 179 ALA A 192 VAL A 249 PHE A 267 LEU A 319 ALA A 329	BI9 A 501 ( 4.8A) BI9 A 501 (-3.3A) None BI9 A 501 ( 4.2A) BI9 A 501 (-4.7A) NH4 A 506 ( 3.7A)	0.90A	5l2tA-6bqlA: 8.0	5l2tA-6bqlA: 13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	GLY A 135 VAL A 142 ALA A 155 VAL A 212 PHE A 230 LEU A 282 ALA A 292	H1N A 501 ( 3.8A) H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-4.9A) H1N A 501 (-3.7A) H1N A 501 (-4.8A) H1N A 501 ( 3.9A)	0.75A	5l2tA-6ccfA: 8.3	5l2tA-6ccfA: 15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	ILE A 134 GLY A 135 VAL A 142 ALA A 155 VAL A 212 PHE A 230 LEU A 282	H1N A 501 (-4.3A) H1N A 501 ( 3.8A) H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-4.9A) H1N A 501 (-3.7A) H1N A 501 (-4.8A)	1.05A	5l2tA-6ccfA: 8.3	5l2tA-6ccfA: 15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	6	VAL U 28 ALA U 42 VAL U 75 ASP U 98 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.86A	5l2tA-6fdyU: 7.3	5l2tA-6fdyU: undetectable

[["5L2T_A_6ZZA900_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 133;ALA A 143","None","0.70A","5l2tA-1h4lA:14.5","5l2tA-1h4lA:45.28"],["5L2T_A_6ZZA900_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ILE A  10;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 133","None","0.90A","5l2tA-1h4lA:14.5","5l2tA-1h4lA:45.28"],["5L2T_A_6ZZA900_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ILE A  10;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133","None","0.79A","5l2tA-1h4lA:14.5","5l2tA-1h4lA:45.28"],["5L2T_A_6ZZA900_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133;ALA A 143","None","0.67A","5l2tA-1h4lA:14.5","5l2tA-1h4lA:45.28"],["5L2T_A_6ZZA900_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",9,"ILE A 580;GLY A 581;VAL A 588;ALA A 606;VAL A 638;PHE A 654;ASP A 661;LEU A 731;ALA A 741","None","0.87A","5l2tA-1lufA:7.1","5l2tA-1lufA:26.98"],["5L2T_A_6ZZA900_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 638;PHE A 654;ASP A 661;LEU A 731;ALA A 741;ASP A 742","None","0.83A","5l2tA-1lufA:7.1","5l2tA-1lufA:26.98"],["5L2T_A_6ZZA900_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None","0.86A","5l2tA-1rjbA:6.6","5l2tA-1rjbA:25.86"],["5L2T_A_6ZZA900_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",6,"GLY A 370;VAL A 377;ALA A 389;VAL A 419;PHE A 435;LEU A 489","None","0.86A","5l2tA-1snxA:8.5","5l2tA-1snxA:27.30"],["5L2T_A_6ZZA900_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"GLY A 596;VAL A 603;ALA A 621;VAL A 654;ASP A 677;LEU A 799","None;STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-4.3A);None;STI A   3 (-4.4A)","0.89A","5l2tA-1t46A:22.1","5l2tA-1t46A:26.02"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",7,"ALA A  30;VAL A  63;PHE A  79;HIS A  81;ASP A  85;LEU A 132;ASP A 143","None","1.08A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",8,"GLY A  11;ALA A  30;VAL A  63;PHE A  79;HIS A  81;ASP A  85;LEU A 132;ALA A 142","None","0.67A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",8,"GLY A  11;VAL A  18;ALA A  30;VAL A  63;PHE A  79;HIS A  81;LEU A 132;ALA A 142","None","0.74A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",8,"ILE A  10;GLY A  11;ALA A  30;VAL A  63;PHE A  79;HIS A  81;ASP A  85;LEU A 132","None","1.06A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",8,"ILE A  10;GLY A  11;VAL A  18;ALA A  30;VAL A  63;PHE A  79;HIS A  81;LEU A 132","None","1.05A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",7,"VAL A  18;ALA A  30;VAL A  63;PHE A  79;HIS A  81;LEU A 132;ASP A 143","None","1.21A","5l2tA-1v0bA:17.5","5l2tA-1v0bA:45.31"],["5L2T_A_6ZZA900_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"ALA A 184;VAL A 220;PHE A 236;LEU A 290;ALA A 319;ASP A 320","None","0.83A","5l2tA-2eu9A:11.7","5l2tA-2eu9A:30.47"],["5L2T_A_6ZZA900_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"GLY A 163;VAL A 170;ALA A 184;VAL A 220;PHE A 236;LEU A 290;ALA A 319","None","0.83A","5l2tA-2eu9A:11.7","5l2tA-2eu9A:30.47"],["5L2T_A_6ZZA900_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"GLY A 249;VAL A 256;ALA A 269;VAL A 299;LEU A 370;ALA A 380","None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.6A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.74A","5l2tA-2hz0A:23.2","5l2tA-2hz0A:25.95"],["5L2T_A_6ZZA900_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",8,"GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 134;ALA A 144","None","0.80A","5l2tA-2jgzA:19.3","5l2tA-2jgzA:48.69"],["5L2T_A_6ZZA900_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"GLY A  11;VAL A  64;PHE A  80;ASP A  86;LEU A 134;ALA A 144;ASP A 145","None","0.93A","5l2tA-2jgzA:19.3","5l2tA-2jgzA:48.69"],["5L2T_A_6ZZA900_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  31;PHE A  80;ASP A  86;LEU A 134","None","1.03A","5l2tA-2jgzA:19.3","5l2tA-2jgzA:48.69"],["5L2T_A_6ZZA900_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;GLY A 429;VAL A 436;ALA A 452;VAL A 484;LEU A 553","BII A1687 (-3.8A);BII A1687 ( 3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);None;BII A1687 (-4.2A)","0.97A","5l2tA-2jkmA:10.4","5l2tA-2jkmA:26.58"],["5L2T_A_6ZZA900_1","2pmi","Saccharomyces cerevisiae","CYCLIN-DEPENDENT PROTEIN KINASE PHO85","PF00069(Pkinase)",6,"VAL A  21;ALA A  34;VAL A  66;PHE A  82;ASP A  88;LEU A 140","AGS A3001 (-4.4A);AGS A3001 (-3.5A);None;None;None;None","0.91A","5l2tA-2pmiA:14.5","5l2tA-2pmiA:41.47"],["5L2T_A_6ZZA900_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"GLY A  83;VAL A  90;ALA A 103;VAL A 137;ASP A 160;LEU A 205;ALA A 215","ANP A1480 ( 4.3A);None;ANP A1480 ( 3.9A);ANP A1480 (-4.7A);ANP A1480 (-4.0A);ANP A1480 ( 4.7A);ANP A1480 ( 4.1A)","0.92A","5l2tA-2v55A:7.5","5l2tA-2v55A:26.20"],["5L2T_A_6ZZA900_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ILE A  82;GLY A  83;VAL A  90;ALA A 103;VAL A 137;ASP A 160;LEU A 205","None;ANP A1480 ( 4.3A);None;ANP A1480 ( 3.9A);ANP A1480 (-4.7A);ANP A1480 (-4.0A);ANP A1480 ( 4.7A)","1.21A","5l2tA-2v55A:7.5","5l2tA-2v55A:26.20"],["5L2T_A_6ZZA900_1","2vd5","Homo sapiens","DMPK PROTEIN","PF00069(Pkinase)",6,"VAL A  85;ALA A  98;ASP A 155;THR A 158;LEU A 202;ALA A 212","BI8 A1417 ( 4.7A);BI8 A1417 ( 3.8A);None;None;BI8 A1417 (-4.8A);BI8 A1417 ( 4.1A)","0.79A","5l2tA-2vd5A:5.3","5l2tA-2vd5A:24.94"],["5L2T_A_6ZZA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",9,"GLY B  13;ALA B  33;VAL B  72;PHE B  93;HIS B  95;ASP B  99;THR B 102;LEU B 147;ALA B 157","None","0.72A","5l2tA-2w9fB:12.0","5l2tA-2w9fB:69.11"],["5L2T_A_6ZZA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",7,"GLY B  13;HIS B  95;ASP B  99;THR B 102;LEU B 147;ALA B 157;ASP B 158","None","1.07A","5l2tA-2w9fB:12.0","5l2tA-2w9fB:69.11"],["5L2T_A_6ZZA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",7,"GLY B  15;ALA B  33;VAL B  72;PHE B  93;ASP B  99;LEU B 147;ALA B 157","None","1.45A","5l2tA-2w9fB:12.0","5l2tA-2w9fB:69.11"],["5L2T_A_6ZZA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",10,"ILE B  12;GLY B  13;VAL B  20;ALA B  33;VAL B  72;PHE B  93;HIS B  95;THR B 102;LEU B 147;ALA B 157","None","0.93A","5l2tA-2w9fB:12.0","5l2tA-2w9fB:69.11"],["5L2T_A_6ZZA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",8,"ILE B  12;GLY B  13;VAL B  20;HIS B  95;THR B 102;LEU B 147;ALA B 157;ASP B 158","None","1.29A","5l2tA-2w9fB:12.0","5l2tA-2w9fB:69.11"],["5L2T_A_6ZZA900_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"GLY A  69;VAL A  76;ALA A  92;VAL A 125;ASP A 148;THR A 151;LEU A 194","STU A   1 (-3.3A);None;STU A   1 (-3.3A);None;STU A   1 (-3.8A);None;STU A   1 (-4.6A)","0.87A","5l2tA-2z7rA:8.7","5l2tA-2z7rA:29.55"],["5L2T_A_6ZZA900_1","3bhh","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II BETA CHAIN","PF00069(Pkinase)",7,"VAL A  28;ALA A  41;VAL A  74;PHE A  90;LEU A 143;ALA A 156;ASP A 157","5CP A 600 ( 4.4A);5CP A 600 (-3.6A);5CP A 600 ( 4.7A);5CP A 600 ( 4.3A);5CP A 600 (-4.4A);5CP A 600 ( 3.9A);5CP A 600 (-3.5A)","0.77A","5l2tA-3bhhA:7.4","5l2tA-3bhhA:30.68"],["5L2T_A_6ZZA900_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",7,"ILE A  18;GLY A  19;VAL A  26;ALA A  39;VAL A  75;PHE A  91;LEU A 148","3AM A 338 (-4.5A);None;3AM A 338 ( 4.1A);3AM A 338 (-3.3A);None;3AM A 338 (-3.6A);3AM A 338 (-4.7A)","1.12A","5l2tA-3c0iA:7.8","5l2tA-3c0iA:26.49"],["5L2T_A_6ZZA900_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",7,"ILE A  23;GLY A  24;VAL A  31;ALA A  44;VAL A  76;LEU A 153;ALA A 163","ANP A   1 (-4.2A);ANP A   1 (-3.3A);ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None; MG A 296 ( 3.9A)","0.93A","5l2tA-3dakA:22.1","5l2tA-3dakA:26.88"],["5L2T_A_6ZZA900_1","3f2a","Homo sapiens","PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE PIM-1","PF00069(Pkinase)",6,"GLY A  45;VAL A  52;ALA A  65;ASP A 128;LEU A 174;ASP A 186","985 A   1 ( 3.9A);985 A   1 (-4.5A);985 A   1 (-3.5A);985 A   1 (-4.7A);985 A   1 (-4.8A);985 A   1 ( 4.0A)","0.94A","5l2tA-3f2aA:7.8","5l2tA-3f2aA:26.61"],["5L2T_A_6ZZA900_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",9,"ILE A  25;GLY A  26;VAL A  33;ALA A  46;VAL A  79;PHE A 103;ASP A 109;LEU A 156;ALA A 166","None","0.83A","5l2tA-3mi9A:12.9","5l2tA-3mi9A:36.87"],["5L2T_A_6ZZA900_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",6,"VAL A  79;PHE A 103;ASP A 109;LEU A 156;ALA A 166;ASP A 167","None","0.73A","5l2tA-3mi9A:12.9","5l2tA-3mi9A:36.87"],["5L2T_A_6ZZA900_1","3mtl","Homo sapiens","CELL DIVISION PROTEIN KINASE 16","PF00069(Pkinase)",7,"GLY A 172;VAL A 179;ALA A 192;VAL A 224;PHE A 240;ASP A 246;LEU A 293","FEF A 668 ( 4.2A);FEF A 668 (-4.9A);FEF A 668 (-3.3A);FEF A 668 (-4.7A);FEF A 668 ( 4.3A);FEF A 668 ( 4.3A);FEF A 668 (-4.2A)","0.85A","5l2tA-3mtlA:18.2","5l2tA-3mtlA:39.60"],["5L2T_A_6ZZA900_1","3mtl","Homo sapiens","CELL DIVISION PROTEIN KINASE 16","PF00069(Pkinase)",7,"VAL A 179;ALA A 192;VAL A 224;PHE A 240;ASP A 246;LEU A 293;ALA A 303","FEF A 668 (-4.9A);FEF A 668 (-3.3A);FEF A 668 (-4.7A);FEF A 668 ( 4.3A);FEF A 668 ( 4.3A);FEF A 668 (-4.2A);FEF A 668 ( 4.0A)","0.87A","5l2tA-3mtlA:18.2","5l2tA-3mtlA:39.60"],["5L2T_A_6ZZA900_1","3oz6","Cryptosporidium parvum","MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE\/THREONINE PROTEIN KINASE","PF00069(Pkinase)",7,"VAL A  25;ALA A  38;VAL A  72;PHE A  90;ASP A  96;LEU A 141;ALA A 151","None","0.91A","5l2tA-3oz6A:14.3","5l2tA-3oz6A:30.67"],["5L2T_A_6ZZA900_1","3qfv","Homo sapiens","CDC42BPB PROTEIN","PF00069(Pkinase)",7,"GLY A  83;VAL A  90;ALA A 103;ASP A 160;THR A 163;LEU A 207;ALA A 217","NM7 A 416 (-3.0A);NM7 A 416 (-3.7A);NM7 A 416 ( 3.7A);None;None;NM7 A 416 ( 4.2A);NM7 A 416 ( 4.5A)","0.80A","5l2tA-3qfvA:6.8","5l2tA-3qfvA:25.98"],["5L2T_A_6ZZA900_1","3qfv","Homo sapiens","CDC42BPB PROTEIN","PF00069(Pkinase)",7,"GLY A  83;VAL A  90;ASP A 160;THR A 163;LEU A 207;ALA A 217;ASP A 218","NM7 A 416 (-3.0A);NM7 A 416 (-3.7A);None;None;NM7 A 416 ( 4.2A);NM7 A 416 ( 4.5A);EDO A 417 (-3.7A)","0.89A","5l2tA-3qfvA:6.8","5l2tA-3qfvA:25.98"],["5L2T_A_6ZZA900_1","3qfv","Homo sapiens","CDC42BPB PROTEIN","PF00069(Pkinase)",7,"ILE A  82;GLY A  83;VAL A  90;ALA A 103;ASP A 160;THR A 163;LEU A 207","None;NM7 A 416 (-3.0A);NM7 A 416 (-3.7A);NM7 A 416 ( 3.7A);None;None;NM7 A 416 ( 4.2A)","1.10A","5l2tA-3qfvA:6.8","5l2tA-3qfvA:25.98"],["5L2T_A_6ZZA900_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",6,"GLY A 362;VAL A 369;ALA A 382;ASP A 440;LEU A 486;ALA A 496","07U A   1 ( 4.2A);07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 (-3.9A);07U A   1 (-4.3A);07U A   1 ( 4.0A)","0.86A","5l2tA-3txoA:19.9","5l2tA-3txoA:27.27"],["5L2T_A_6ZZA900_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 552;ALA A 570;VAL A 601;PHE A 617;ASP A 624;LEU A 686","None;0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);None;0F4 A 902 (-4.5A)","0.86A","5l2tA-3v5qA:21.9","5l2tA-3v5qA:27.74"],["5L2T_A_6ZZA900_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"GLY A  76;VAL A  83;ALA A  96;VAL A 128;HIS A 146;LEU A 198","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);ANP A 401 ( 4.9A);ANP A 401 (-4.8A)","0.87A","5l2tA-3wigA:7.2","5l2tA-3wigA:31.83"],["5L2T_A_6ZZA900_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A)","0.75A","5l2tA-4aguA:17.1","5l2tA-4aguA:35.54"],["5L2T_A_6ZZA900_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 568;ALA A 586;VAL A 617;PHE A 633;ASP A 640;LEU A 699","None;LTI A1839 (-3.3A);None;LTI A1839 (-3.5A);None;LTI A1839 (-4.2A)","0.86A","5l2tA-4at3A:6.8","5l2tA-4at3A:27.38"],["5L2T_A_6ZZA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"GLY A  84;ALA A 104;ASP A 161;THR A 164;LEU A 208;ALA A 218","None;EDO A1420 (-3.4A);None;None;EDO A1420 ( 4.8A);None","0.95A","5l2tA-4aw2A:7.0","5l2tA-4aw2A:25.73"],["5L2T_A_6ZZA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"GLY A  84;ASP A 161;THR A 164;LEU A 208;ALA A 218;ASP A 219","None;None;None;EDO A1420 ( 4.8A);None;None","0.94A","5l2tA-4aw2A:7.0","5l2tA-4aw2A:25.73"],["5L2T_A_6ZZA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"ILE A  83;VAL A  91;ALA A 104;ASP A 161;THR A 164;LEU A 208","None;None;EDO A1420 (-3.4A);None;None;EDO A1420 ( 4.8A)","0.98A","5l2tA-4aw2A:7.0","5l2tA-4aw2A:25.73"],["5L2T_A_6ZZA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A  91;ALA A 104;ASP A 161;THR A 164;LEU A 208;ALA A 218","None;EDO A1420 (-3.4A);None;None;EDO A1420 ( 4.8A);None","0.73A","5l2tA-4aw2A:7.0","5l2tA-4aw2A:25.73"],["5L2T_A_6ZZA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A  91;ASP A 161;THR A 164;LEU A 208;ALA A 218;ASP A 219","None;None;None;EDO A1420 ( 4.8A);None;None","0.78A","5l2tA-4aw2A:7.0","5l2tA-4aw2A:25.73"],["5L2T_A_6ZZA900_1","4bbm","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 2","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133;ASP A 144","None;TC0 A 500 (-3.5A);TC0 A 500 (-4.7A);TC0 A 500 (-3.4A);TC0 A 500 (-4.3A);TC0 A 500 (-4.8A)","0.71A","5l2tA-4bbmA:13.9","5l2tA-4bbmA:33.62"],["5L2T_A_6ZZA900_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"GLY A  43;VAL A  50;ALA A  63;VAL A  94;LEU A 164;ALA A 174","XZN A1317 ( 4.9A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.93A","5l2tA-4bc6A:20.7","5l2tA-4bc6A:28.83"],["5L2T_A_6ZZA900_1","4bgq","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 5","PF00069(Pkinase)",6,"GLY A  20;VAL A  27;ALA A  40;VAL A  73;PHE A  89;LEU A 142","None;38R A1000 ( 4.8A);38R A1000 (-3.4A);None;38R A1000 ( 3.8A);38R A1000 ( 4.5A)","0.68A","5l2tA-4bgqA:17.1","5l2tA-4bgqA:35.76"],["5L2T_A_6ZZA900_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A 671;ALA A 684;VAL A 721;ASP A 744;LEU A 789;ALA A 799","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-4.0A);AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.74A","5l2tA-4crsA:8.0","5l2tA-4crsA:26.30"],["5L2T_A_6ZZA900_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"ALA A 588;VAL A 620;ASP A 643;THR A 646;LEU A 690;ASP A 701","GUI A 901 (-3.4A);None;GUI A 901 ( 4.8A);GUI A 901 ( 3.8A);GUI A 901 (-4.3A);GUI A 901 ( 4.1A)","0.86A","5l2tA-4e93A:7.7","5l2tA-4e93A:22.06"],["5L2T_A_6ZZA900_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ILE A 567;GLY A 568;ALA A 588;VAL A 620;ASP A 643;THR A 646;LEU A 690","GUI A 901 (-4.0A);GUI A 901 ( 4.3A);GUI A 901 (-3.4A);None;GUI A 901 ( 4.8A);GUI A 901 ( 3.8A);GUI A 901 (-4.3A)","1.01A","5l2tA-4e93A:7.7","5l2tA-4e93A:22.06"],["5L2T_A_6ZZA900_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"ILE A 567;GLY A 568;VAL A 575;ALA A 588;VAL A 620;ASP A 643;LEU A 690","GUI A 901 (-4.0A);GUI A 901 ( 4.3A);GUI A 901 (-4.5A);GUI A 901 (-3.4A);None;GUI A 901 ( 4.8A);GUI A 901 (-4.3A)","1.01A","5l2tA-4e93A:7.7","5l2tA-4e93A:22.06"],["5L2T_A_6ZZA900_1","4ez5","Homo sapiens","CYCLIN-DEPENDENT KINASE 6","PF00069(Pkinase)",7,"GLY A  20;VAL A  27;VAL A  77;PHE A  98;ASP A 104;THR A 106;LEU A 152","None;None;0RS A 900 (-4.4A);0RS A 900 (-4.5A);0RS A 900 (-4.2A);None;0RS A 900 (-4.3A)","1.44A","5l2tA-4ez5A:24.4","5l2tA-4ez5A:100.00"],["5L2T_A_6ZZA900_1","4ez5","Homo sapiens","CYCLIN-DEPENDENT KINASE 6","PF00069(Pkinase)",12,"ILE A  19;GLY A  20;VAL A  27;ALA A  41;VAL A  77;PHE A  98;HIS A 100;ASP A 104;THR A 107;LEU A 152;ALA A 162;ASP A 163","0RS A 900 (-4.1A);None;None;0RS A 900 ( 3.7A);0RS A 900 (-4.4A);0RS A 900 (-4.5A);0RS A 900 (-4.1A);0RS A 900 (-4.2A);0RS A 900 (-4.2A);0RS A 900 (-4.3A);0RS A 900 (-3.6A);0RS A 900 (-3.6A)","0.66A","5l2tA-4ez5A:24.4","5l2tA-4ez5A:100.00"],["5L2T_A_6ZZA900_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 516;VAL A 523;ALA A 541;VAL A 572;PHE A 588;ASP A 595;LEU A 656","None","0.91A","5l2tA-4f0iA:21.9","5l2tA-4f0iA:27.86"],["5L2T_A_6ZZA900_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A1123;VAL A1130;ALA A1148;VAL A1180;ASP A1203;LEU A1256","0UV A1501 ( 4.3A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.9A);0UV A1501 ( 4.6A);0UV A1501 (-4.6A)","0.94A","5l2tA-4fodA:7.5","5l2tA-4fodA:24.72"],["5L2T_A_6ZZA900_1","4fzd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MST4","PF00069(Pkinase)",6,"ILE B  30;GLY B  31;VAL B  38;ALA B  51;LEU B 151;ALA B 161","GOL B1000 (-4.1A);None;None;GOL B1000 ( 4.3A);GOL B1000 ( 4.4A);None","0.64A","5l2tA-4fzdB:23.8","5l2tA-4fzdB:26.10"],["5L2T_A_6ZZA900_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"GLY A 829;VAL A 836;ALA A 853;VAL A 884;LEU A 956;ALA A 966","19S A1201 (-3.7A);19S A1201 (-4.4A);19S A1201 (-3.3A);None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.83A","5l2tA-4hviA:23.1","5l2tA-4hviA:26.22"],["5L2T_A_6ZZA900_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",6,"ALA A 648;VAL A 685;ASP A 708;LEU A 753;ALA A 763;ASP A 764","None","0.93A","5l2tA-4otdA:7.3","5l2tA-4otdA:27.42"],["5L2T_A_6ZZA900_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None;None;P30 A1001 (-3.4A);None;P30 A1001 (-3.7A);None;P30 A1001 (-4.6A)","0.81A","5l2tA-4rt7A:6.8","5l2tA-4rt7A:23.37"],["5L2T_A_6ZZA900_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None;P30 A1001 ( 4.8A);P30 A1001 (-3.5A);None;P30 A1001 ( 4.3A);None;P30 A1001 (-4.3A)","0.76A","5l2tA-4xufA:7.0","5l2tA-4xufA:28.74"],["5L2T_A_6ZZA900_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 135;ALA A 145","None","0.88A","5l2tA-4yc6A:14.8","5l2tA-4yc6A:45.60"],["5L2T_A_6ZZA900_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;VAL A  64;ASP A  86;LEU A 135;ALA A 145;ASP A 146","None","0.98A","5l2tA-4yc6A:14.8","5l2tA-4yc6A:45.60"],["5L2T_A_6ZZA900_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 135;ALA A 145","None","0.69A","5l2tA-4yc6A:14.8","5l2tA-4yc6A:45.60"],["5L2T_A_6ZZA900_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"GLY A 470;VAL A 477;ALA A 488;LEU A 595;ALA A 605;ASP A 606","4CV A 801 ( 3.9A);None;4CV A 801 (-3.5A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A);4CV A 801 (-3.5A)","0.71A","5l2tA-4yffA:21.3","5l2tA-4yffA:26.33"],["5L2T_A_6ZZA900_1","4ylj","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","PF00069(Pkinase)",6,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;PHE A 238;LEU A 294","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-4.2A);None","0.83A","5l2tA-4yljA:12.8","5l2tA-4yljA:29.18"],["5L2T_A_6ZZA900_1","4ylj","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","PF00069(Pkinase)",6,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;VAL A 222;PHE A 238","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;4E1 A 505 (-4.2A)","0.88A","5l2tA-4yljA:12.8","5l2tA-4yljA:29.18"],["5L2T_A_6ZZA900_1","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",6,"GLY A  27;VAL A  34;ALA A  47;HIS A  98;LEU A 149;ALA A 159","None","0.97A","5l2tA-4ynzA:12.2","5l2tA-4ynzA:30.66"],["5L2T_A_6ZZA900_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"VAL A  30;ALA A  44;VAL A  76;ASP A  99;LEU A 145;ALA A 164","51W A 401 ( 4.3A);51W A 401 (-3.4A);None;51W A 401 (-3.8A);51W A 401 (-4.5A);None","0.69A","5l2tA-5ci7A:8.1","5l2tA-5ci7A:29.23"],["5L2T_A_6ZZA900_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",6,"ILE A  81;GLY A  82;VAL A  89;ALA A 102;VAL A 134;LEU A 211","ANP A 401 ( 4.1A);ANP A 401 ( 3.9A);ANP A 401 (-4.0A);ANP A 401 ( 4.0A);None;None","0.96A","5l2tA-5dbxA:21.4","5l2tA-5dbxA:27.27"],["5L2T_A_6ZZA900_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"GLY A 600;VAL A 607;ALA A 625;VAL A 658;ASP A 681;LEU A 825","None;748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 ( 4.8A);None;748 A1001 (-4.3A)","0.84A","5l2tA-5grnA:6.7","5l2tA-5grnA:26.86"],["5L2T_A_6ZZA900_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",6,"GLY A  21;VAL A  28;ALA A  41;VAL A  74;PHE A  90;ALA A 156","ADP A 301 (-3.6A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;None;ADP A 301 ( 4.8A)","0.83A","5l2tA-5hu3A:7.8","5l2tA-5hu3A:31.56"],["5L2T_A_6ZZA900_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"GLY A  28;ALA A  50;PHE A  97;ASP A 103;LEU A 158;ALA A 172","6A7 A 401 (-3.6A);6A7 A 401 (-3.3A);6A7 A 401 (-3.8A);6A7 A 401 ( 4.9A);6A7 A 401 (-4.8A);6A7 A 401 ( 4.1A)","0.83A","5l2tA-5idnA:14.5","5l2tA-5idnA:32.80"],["5L2T_A_6ZZA900_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"GLY A  28;VAL A  35;ALA A  50;PHE A  97;LEU A 158;ALA A 172","6A7 A 401 (-3.6A);6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);6A7 A 401 (-3.8A);6A7 A 401 (-4.8A);6A7 A 401 ( 4.1A)","0.78A","5l2tA-5idnA:14.5","5l2tA-5idnA:32.80"],["5L2T_A_6ZZA900_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"GLY A  23;VAL A  30;ALA A  43;VAL A  74;ALA A 153;ASP A 154","None;6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;6G2 A 901 ( 4.2A);6G2 A 901 (-3.4A)","0.94A","5l2tA-5j5tA:20.7","5l2tA-5j5tA:26.77"],["5L2T_A_6ZZA900_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"VAL A  30;ALA A  43;VAL A  74;LEU A 143;ALA A 153;ASP A 154","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A);6G2 A 901 (-3.4A)","0.86A","5l2tA-5j5tA:20.7","5l2tA-5j5tA:26.77"],["5L2T_A_6ZZA900_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",7,"ILE A 396;GLY A 397;VAL A 404;ALA A 417;VAL A 449;ASP A 472;LEU A 518","GUI A 701 (-4.1A);GUI A 701 ( 3.8A);GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;None;GUI A 701 (-4.4A)","1.14A","5l2tA-5jznA:8.0","5l2tA-5jznA:31.76"],["5L2T_A_6ZZA900_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",6,"ILE A  41;VAL A  49;ALA A  60;VAL A  94;ASP A 117;LEU A 163","STU A 901 (-4.3A);None;STU A 901 (-3.3A);None;STU A 901 (-4.2A);STU A 901 (-4.5A)","0.74A","5l2tA-5lohA:8.4","5l2tA-5lohA:27.09"],["5L2T_A_6ZZA900_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",6,"ILE A 155;GLY A 156;VAL A 163;ALA A 176;PHE A 228;LEU A 282","7A7 A 501 ( 4.3A);7A7 A 501 (-3.2A);7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-3.7A);7A7 A 501 (-4.9A)","0.86A","5l2tA-5lxdA:16.3","5l2tA-5lxdA:26.18"],["5L2T_A_6ZZA900_1","5myv","Homo sapiens","SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2","PF00069(Pkinase)",6,"GLY A  99;VAL A 106;ALA A 119;VAL A 157;PHE A 177;LEU A 232","W4A A 716 ( 4.0A);W4A A 716 ( 4.7A);W4A A 716 ( 3.9A);DMS A 717 (-4.3A);DMS A 717 ( 3.9A);None","0.94A","5l2tA-5myvA:14.5","5l2tA-5myvA:26.75"],["5L2T_A_6ZZA900_1","5ncl","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE CBK1","no annotation",7,"ILE A 358;GLY A 359;ALA A 379;VAL A 413;ASP A 436;THR A 439;LEU A 482","ANP A 801 (-4.2A);ANP A 801 ( 4.1A);ANP A 801 ( 3.9A);ANP A 801 ( 4.9A);ANP A 801 (-3.4A);None;ANP A 801 (-4.8A)","0.86A","5l2tA-5nclA:7.3","5l2tA-5nclA:16.60"],["5L2T_A_6ZZA900_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"ILE A  98;GLY A  99;ALA A 119;VAL A 153;ASP A 176;LEU A 221;ALA A 231","None","1.13A","5l2tA-5u7qA:7.6","5l2tA-5u7qA:26.05"],["5L2T_A_6ZZA900_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"ILE A  98;VAL A 106;ALA A 119;VAL A 153;ASP A 176;LEU A 221;ALA A 231","None","1.13A","5l2tA-5u7qA:7.6","5l2tA-5u7qA:26.05"],["5L2T_A_6ZZA900_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",7,"ILE A  75;GLY A  76;VAL A  83;ALA A  95;VAL A 125;LEU A 206;ALA A 216","ANP A1000 (-4.2A);ANP A1000 ( 3.8A);ANP A1000 (-4.1A);ANP A1000 (-3.2A);None;ANP A1000 (-4.5A); MG A1001 ( 4.4A)","0.98A","5l2tA-5xd6A:6.3","5l2tA-5xd6A:13.53"],["5L2T_A_6ZZA900_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",7,"GLY A 734;VAL A 787;PHE A 813;ASP A 819;LEU A 866;ALA A 876;ASP A 877","CJM A1102 (-3.4A);None;CJM A1102 ( 4.4A);CJM A1102 (-4.1A);CJM A1102 (-4.4A);CJM A1102 (-3.6A); MG A1101 (-2.5A)","0.96A","5l2tA-6b3eA:13.4","5l2tA-6b3eA:16.06"],["5L2T_A_6ZZA900_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",8,"ILE A 733;GLY A 734;ALA A 754;VAL A 787;PHE A 813;ASP A 819;LEU A 866;ALA A 876","CJM A1102 (-3.4A);CJM A1102 (-3.4A);CJM A1102 (-3.1A);None;CJM A1102 ( 4.4A);CJM A1102 (-4.1A);CJM A1102 (-4.4A);CJM A1102 (-3.6A)","1.03A","5l2tA-6b3eA:13.4","5l2tA-6b3eA:16.06"],["5L2T_A_6ZZA900_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",8,"ILE A 733;VAL A 741;ALA A 754;VAL A 787;PHE A 813;ASP A 819;LEU A 866;ALA A 876","CJM A1102 (-3.4A);None;CJM A1102 (-3.1A);None;CJM A1102 ( 4.4A);CJM A1102 (-4.1A);CJM A1102 (-4.4A);CJM A1102 (-3.6A)","0.91A","5l2tA-6b3eA:13.4","5l2tA-6b3eA:16.06"],["5L2T_A_6ZZA900_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"VAL A 179;ALA A 192;VAL A 249;PHE A 267;LEU A 319;ALA A 329","BI9 A 501 ( 4.8A);BI9 A 501 (-3.3A);None;BI9 A 501 ( 4.2A);BI9 A 501 (-4.7A);NH4 A 506 ( 3.7A)","0.90A","5l2tA-6bqlA:8.0","5l2tA-6bqlA:13.64"],["5L2T_A_6ZZA900_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"GLY A 135;VAL A 142;ALA A 155;VAL A 212;PHE A 230;LEU A 282;ALA A 292","H1N A 501 ( 3.8A);H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-4.9A);H1N A 501 (-3.7A);H1N A 501 (-4.8A);H1N A 501 ( 3.9A)","0.75A","5l2tA-6ccfA:8.3","5l2tA-6ccfA:15.65"],["5L2T_A_6ZZA900_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"ILE A 134;GLY A 135;VAL A 142;ALA A 155;VAL A 212;PHE A 230;LEU A 282","H1N A 501 (-4.3A);H1N A 501 ( 3.8A);H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-4.9A);H1N A 501 (-3.7A);H1N A 501 (-4.8A)","1.05A","5l2tA-6ccfA:8.3","5l2tA-6ccfA:15.65"],["5L2T_A_6ZZA900_1","6fdy","-","-","no annotation",6,"VAL U  28;ALA U  42;VAL U  75;ASP U  98;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.86A","5l2tA-6fdyU:7.3","5l2tA-6fdyU:undetectable"]]